COMBINED CSF α-SYN RT-QuIC, CSF NFL AND MIDBRAIN-PONS PLANIMETRY IN DEGENERATIVE PARKINSONISMS: FROM BEDSIDE TO BENCH, AND BACK AGAIN
Objective: (1) to assess the combined diagnostic ability of CSF NFL, CSF RT-QuIC α-SYN and midbrain/pons MRI measures in degenerative parkinsonisms; (2) to interpret results…The acceptability of wearable devices to measure mobility in people with Parkinson’s Disease: observations from Mobilise-D
Objective: To explore the acceptability of wearable devices to remotely measure mobility in the Mobilise-D technical validation study (TVS). Background: When deploying tools to monitor…Highlighting the dystonic phenotype related to GNAO1
Objective: To characterize the clinical and genetic features of patients with mild GNAO1-related phenotype with prominent movement disorders. Background: Most reported patients carrying GNAO1 mutations…Developing infrastructure for a multi-arm multi-stage trial in Parkinson’s
Objective: To scope and develop infrastructure for the first multi-arm multi-stage (MAMS) platform trial for Parkinson’s disease, the Edmond J Safra ACT-PD initiative (EJS ACT-PD).…EFFECTS OF DOPAMINERGIC MEDICATION ON REACTIVE AND PROACTIVE INHIBITORY CONTROL
Objective: In this study, we aim to address the effects of dopaminergic treatment (DT) on the two domains of motor inhibition [1], i.e., reactive (the…COVID-19 encephalitis with anti-mGluR1 antibody-positive cerebellar ataxia
Objective: To describe a unique case of anti-metabotropic glutamate receptor 1 (mGluR1) antibody (Ab)-mediated cerebellar ataxia post-COVID-19 encephalitis. Background: Cerebellar syndrome is increasingly recognised in…Japanese cases of Sez6l2 autoimmunity
Objective: We aimed to establish a method for measuring anti-Sez6l2 antibody and to clarify how many patients with anti-Sez6l2 antibody-associated cerebellar ataxia (CA) exist in…Determination of metabotropic glutamate receptor 2/3 distribution with [3H]-LY-341,495 in Parkinson’s disease patients with visual hallucinations
Objective: To determine the distribution and levels of metabotropic glutamate 2/3 (mGlu2/3) receptors in brain tissue from patients with Parkinson’s disease (PD) with visual hallucinations (VHs).…Open-Label, Single-Arm, Exploratory Trial of Opicapone: Status Update of the OASIS (OPICAPONE IN SLEEP DISORDER) Study
Objective: This study aims to evaluate the effects of opicapone (OPC) 50 mg treatment on sleep disorders in patients with Parkinson’s disease (PD) and ‘wearing-off’.…Socio-economic factors influencing Parkinson’s disease self-management
Objective: To identify the socioeconomical factors associated with self-management Parkinson’s disease (PD). Background: Understanding and evaluating how PD patients manage their disease is paramount to…
- « Previous Page
- 1
- …
- 76
- 77
- 78
- 79
- 80
- …
- 153
- Next Page »